DNase activity
MtbCsm DNase activity is uncoupled from target RNA recognition in contrast to other type III systems. NT: non-complementary RNA; AT: anti-tag RNA.
Activation of the Ancillary Nuclease Csm6
Csm ATP RNA Csm6 requires activation by cyclic hexa-adenylate (cA6) for RNase function. Only RNA that is complementary to the crRNA spacer and noncomplementary to the repeat-derived handle triggers cOA production by the Cas10 cyclase domain. WT: mtbCsm wild type; cy: mtbCsm cyclase mutant; c3: mtbCsm Csm3 active site mutant; T: target RNA; NT: nontarget RNA; AT: anti-tag RNA. 
Plasmid Immunity Assay

E. coli
TetR pBAD Target Selective Growth
Outline of plasmid immunity assay. E. coli cells harbouring mtbCsm effector complex and target specifying CRISPR array (CA) are transformed with target plasmid, serially diluted and applied onto selective medium.
Plasmid immunity conferred by mtbCsm is dependent on the presence of crRNA-complementary sequence in the incoming plasmid and on the transcription of the target.
MtbCsm-dependent plasmid immunity in the heterologous host E. coli does not require target mRNA cleavage by Csm3 nor an active HD nuclease domain. It is, however, strictly dependent on the presence of the cOAactivated ribonuclease Csm6 and the production of cOA signal by the cyclase domain.
This project has been funded by a Challenge grant of the Royal Society (CH160014) to M. F. White. The mtbCsm effector complex can be heterologously expressed in active form as shown by both in vitro and in vivo assays. In the heterologous system, immunity appears to be solely dependent on Csm6 activity, however, a requirement for mycobacterial host factors for DNAtargeting cannot be excluded at this point.
Next steps will be to investigate mtbCsm in relevant mycobacterial hosts to determine the fate of host cells upon CRISPR-Cas activation (cell death, dormancy, recovery) and to investigate whether mtbCsm can be reprogrammed for gene silencing or editing.
